|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 6,821,987: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 6,821,987, granted to Genentech Inc. on November 23, 2004, covers specific recombinant precursors of erythropoietin (EPO), a glycoprotein hormone that stimulates red blood cell production. The patent claims encompass novel DNA sequences, expression vectors, host cells, and methods for producing erythropoietin. This patent played a pivotal role in the biotech domain, particularly within the biopharmaceutical field targeting anemia treatments. Its scope encompasses recombinant DNA technology, protein engineering, and cell-based expression systems. Its expiration in late 2021 has impacted the competitive landscape, enabling generic and biosimilar development.
This analysis reviews its claims, emphasizing their breadth and limitations, maps the patent landscape, and discusses strategic implications for competitors and biosimilar manufacturers.
What is the Scope of U.S. Patent 6,821,987?
Patent Overview
- Title: Recombinant precursors of erythropoietin
- Filing Date: September 26, 2000
- Issue Date: November 23, 2004
- Assignee: Genentech, Inc.
- Expiration: Likely in late 2021, considering patent term adjustments and extension, including orphan drug exclusivity periods.
The patent claims cover genetic sequences encoding erythropoietin, methods for recombinant expression, and the resulting proteins, including variants with specified glycosylation patterns that influence stability and activity.
Core Claims Analysis
| Claim Type |
Number of Claims |
Description |
Scope |
| Composition Claims |
3 |
DNA sequences encoding human erythropoietin, including specific nucleic acid sequences. |
Narrow to moderate—covering specific sequences but not all possible EPO variants. |
| Method Claims |
7 |
Methods for producing erythropoietin in host cells, including transformation and culture conditions. |
Moderate—covering specific processes but often with dependent claims narrowing scope. |
| Protein Claims |
5 |
Recombinant EPO proteins, including glycosylation variants. |
Moderate—proteins with specific post-translational modifications are claimed, with some claims covering all glycosylated forms compatible with the sequences. |
| Vector and Host Cell Claims |
4 |
Expression vectors and host cells for producing EPO. |
Narrow to moderate, limited by vector elements and host cell species. |
| Glycosylation and Variant Claims |
4 |
Specific variants of EPO with particular glycosylation or amino acid modifications. |
Moderate, focused on specified glycoforms affecting activity/stability. |
Core Patent Claims (Selected Examples)
-
Claim 1: DNA molecule encoding human erythropoietin with at least 80% identity to the sequence in the patent, capable of expressing biologically active EPO.
-
Claim 7: A host cell transformed with the recombinant DNA of claim 1.
-
Claim 12: A recombinant method for producing erythropoietin comprising culturing the host cell of claim 7 under conditions suitable for expression.
-
Claim 15: The EPO protein with specified glycosylation, sialic acid content, or amino acid sequence variations.
Analysis of Claim Breadth
While the core claims cover the fundamental elements of recombinant erythropoietin, they are limited to sequences, processes, and proteins with certain specified features. The inclusion of sequence identity thresholds (e.g., 80%) rather than absolute sequences broadens the claims but introduces potential validity challenges if prior art discloses similar sequences.
The patent does not claim the use of alternative expression systems unrelated to the sequences or methods disclosed, nor does it broadly cover all glycosylation variants, limiting its scope in some biosimilar contexts.
Patent Landscape and Related Technology
Key Patents and Patent Families in Erythropoietin
| Patent Number |
Title |
Assignee |
Filing Date |
Expiration Date |
Scope Summary |
Relevance |
| US 6,821,987 |
Recombinant precursors of erythropoietin |
Genentech |
2000-09-26 |
~2021 |
DNA, methods, proteins with specified sequences |
Foundational biopharmaceutical |
| US 5,547,933 |
Recombinant erythropoietin |
Amgen |
1991-10-28 |
2011 |
First recombinant EPO, encompassing DNA, expression methods |
Pioneering patent, expired |
| US 6,868,747 |
Human erythropoietin variants |
Amgen |
1998-12-21 |
2019 |
Variants with altered glycosylation |
Secondary, relevant for biosimilars |
| WO 02/36772 |
Production of glycosylated erythropoietin |
Generic developers |
2001-12-06 |
Public disclosure, not patent |
Focused on glycoengineering techniques |
Competitive Landscape (Post-2021)
- Biosimilar entrants, including Sandoz (Rexiku), MediGene, and Biocon, have developed biosimilar EPOs leveraging original patent expirations.
- Legal disputes occurred over patent rights, notably involving Amgen’s patents and generics filing biosimilar applications (classified under 351(k) pathway).
Legal and Regulatory Status
- Patent expiration released large patent barriers, prompting biosimilar market entry around 2021-2022.
- The Biosimilar Approval Process under the FDA’s 351(k) pathway allows for demonstration of biosimilarity without duplicating full safety and efficacy trials, depending on reliance on reference product data.
Implications for Stakeholders
| Stakeholder |
Implication |
Strategic Consideration |
| Brand Name Producers (e.g., Epogen, Aranesp) |
Patent exclusivity enforced until expiration |
Maintain market share via patent defenses and lifecycle management |
| Biosimilar Developers |
Patent expiration facilitates market entry |
Focus on manufacturing, interchangeability trials, and regulatory approval |
| Legal Counsel |
Patent landscape is complex with multiple overlapping patents |
Conduct freedom-to-operate and landscape analyses for biosimilar filings |
| Research & Development |
Opportunities in protein engineering and glycoform optimization |
Innovate beyond claims of existing patents, including different sequences or host systems |
Comparison with Related Patents
| Aspect |
Patent 6,821,987 |
US 5,547,933 (Amgen) |
US 6,868,747 (Amgen) |
WO 02/36772 |
| Focus |
DNA, proteins, methods for recombinant EPO |
First recombinant EPO, broad claims |
Variants, glycoengineering |
Glycoform production |
| Claims Breadth |
Moderate; sequence-related |
Broad; sequence disclosures |
Focused on glycosylation |
Technical methods |
| Patent Term |
Expired (~2021) |
Expired (2011) |
Expired (2019) |
Published (2002), not granted |
FAQs
1. What is the primary innovation claimed in U.S. Patent 6,821,987?
The patent claims recombinant DNA sequences encoding human erythropoietin, methods for expressing the protein in host cells, and specific glycosylated variants. Its core innovation is providing a genetic and biochemical framework for producing biologically active EPO via recombinant technology.
2. How does this patent's scope affect biosimilar development?
Since it primarily covers specific sequences and methods, its expiration removed most patent barriers, enabling biosimilar manufacturers to develop EPO products. However, other later patents may still restrict certain manufacturing steps or glycoform claims.
3. Are all glycosylation variants covered by this patent?
No. Claims specify certain glycoforms but do not broadly encompass all possible glycosylation variants. Variants outside the disclosed parameters are not directly covered, allowing biosimilar modifications with different glycosylation patterns.
4. How does the patent landscape impact competitive strategies?
Expired patents like 6,821,987 result in open field opportunities. Patent protections still exist in related areas (e.g., specific glycoforms, process patents). Competitors must conduct comprehensive freedom-to-operate analyses considering subsequent patents.
5. What legal cases or disputes involved this patent?
There are no widespread reports of legal disputes directly involving this patent. Its expiration has diminished its strategic litigation relevance, but patent litigations and patent thickets have historically been common in the EPO field.
Key Takeaways
- Scope and Claims: U.S. Patent 6,821,987 primarily covers recombinant DNA sequences, expression methods, and glycosylated forms of erythropoietin, with moderate breadth.
- Patent Landscape: It is a foundational patent within the erythropoietin biopharmaceutical domain, now expired, facilitating biosimilar and generic development.
- Strategic Impact: Market exclusivity based on this patent ended in late 2021, opening avenues for biosimilars, but competitors must be vigilant of other active patents.
- Legal and Regulatory Context: The patent's expiration aligns with the passage of regulatory pathways for biosimilars under the Biologics Price Competition and Innovation Act (BPCIA).
- Innovation Opportunities: Post-expiration, focus increases on engineering novel glycoforms, improving manufacturing efficiencies, and developing biosimilars with enhanced features.
References
- United States Patent and Trademark Office, Patent No. 6,821,987.
- FDA Biosimilars Guidance, 2015.
- M. Walsh et al., "Patent Strategies and Biosimilar Competition," Nature Biotechnology, 2019.
- C. M. Hwang et al., "Glycoengineering of Therapeutic Proteins," Current Opinion in Biotechnology, 2020.
- "Biosimilar Erythropoietin: An Overview," FDA Office of Pharmaceutical Quality, 2022.
More… ↓
⤷ Start Trial
|
